Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
oral administration of Tegio capsules for 12 months for NPC patients with high risk of
metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant
metastasis，safety was also evaluated.